CytoSiteBio (CytoSite), a biotech company developing a novel diagnostic radiopharmaceutical — a Granzyme B imaging agent — sought to evaluate its potential as a companion diagnostic in immuno-oncology. The company recognized the agent's significant scalability and potential for applications beyond its original purpose.
To achieve this, CytoSite required expert guidance to navigate the complex regulatory, clinical, and business challenges associated with this emerging field. CytoSite engaged Bracken for an embedded, integrated partnership — bringing cross-functional expertise in radiopharmaceuticals, clinical trial design, regulatory affairs, and business development to bear on a single, cohesive program.
What CytoSite Was Up Against
Advancing a novel radiopharmaceutical required simultaneous mastery of clinical, regulatory, and commercial complexity — with no established playbook for this specific immuno-oncology context.
Clinical protocol needed to be tailored to immuno-oncology applications while ensuring sustainable scalability
Strict radiopharmaceutical regulatory pathways required navigation while requirements continued to evolve
Production, distribution, and clinical use of the imaging agent demanded a purpose-built services model
Market positioning needed to attract interest from pharma and biotech companies beyond CytoSite's own pipeline
No established playbook for companion diagnostic development in this specific immuno-oncology context
How Bracken Built the Solution
An embedded, interdepartmental partnership integrating clinical, regulatory, and commercial expertise across every stage of development.
Protocol Design
Served as intrinsic clinical partner during early-stage protocol development, ensuring alignment with regulatory guidelines and the Granzyme B agent's intended immuno-oncology applications
Trial Methodology
Developed a trial methodology tailored to both scientific rigor and regulatory demands — establishing the clinical foundation for a clear pathway to approval
Services Model
Designed a scalable radiopharmaceutical services model covering production, distribution, and clinical use — streamlining operations and addressing the unique logistics of diagnostic radiopharmaceuticals
Regulatory Navigation
Provided ongoing regulatory expertise to manage compliance challenges effectively as the radiopharmaceutical landscape continued to evolve
BD Positioning
Supported CytoSite's business development efforts, positioning the Granzyme B imaging agent as a versatile immuno-oncology diagnostic — attracting interest from pharma and biotech partners beyond CytoSite's pipeline
Measurable Outcomes
Bracken's intrinsic, dedicated partnership with CytoSite exemplifies how interdepartmental, integrated expertise in clinical, regulatory, and operational areas can accelerate the development and scalability of innovative technologies. Through an embedded, collaborative approach at every stage, Bracken ensured the Granzyme B imaging agent was positioned for success — transforming it from a promising diagnostic tool to a cornerstone of immuno-oncology diagnostics.
Common Questions About Radiopharmaceutical Development and Companion Diagnostics
Granzyme B is a serine protease released by cytotoxic T cells when they kill cancer cells — making it a direct biomarker of immune-mediated tumor cell death. A Granzyme B imaging agent is a diagnostic radiopharmaceutical designed to detect and quantify this activity in vivo, providing real-time assessment of immunotherapy response. In immuno-oncology, this capability is highly valuable as a companion diagnostic — identifying which patients are responding to immunotherapy and guiding treatment decisions.
Radiopharmaceutical development sits at the intersection of nuclear medicine, oncology, regulatory science, and specialized manufacturing — making it one of the most technically complex areas in drug development. Unique challenges include short radioisotope half-lives requiring rapid production and distribution, specialized GMP manufacturing requirements, distinct regulatory pathways at FDA and international agencies, and the need for purpose-built services models to manage clinical use logistics. Few organizations have deep expertise across all of these dimensions simultaneously.
A scalable radiopharmaceutical services model is the operational infrastructure required to reliably produce, distribute, and administer a radiopharmaceutical in clinical use — from a single trial site to a multi-center global program. It addresses the unique logistics of radioactive materials: short shelf lives, specialized cold chain requirements, site preparation and training, and regulatory compliance across jurisdictions. Designing this model correctly from the outset is critical to both clinical trial execution and eventual commercial scale-up.
Regulatory strategy for a companion diagnostic radiopharmaceutical requires coordinating multiple regulatory tracks simultaneously — the diagnostic device pathway, the pharmaceutical pathway, and in some cases co-development with a therapeutic partner. Early engagement with the FDA and relevant international agencies is essential to align on the intended use, clinical validation requirements, and submission strategy. Bracken integrates regulatory planning from the earliest stages of protocol design — ensuring that the clinical evidence generated is precisely what regulators will need for approval.
